CSF2RB and acute myeloid leukemia: Our results suggest that therapeutic use of peptides blocking the CSF2RB/FLT3-ITD-binding interface might be used to synergize with therapeutic FLT3 kinase inhibitors to improve response and attenuate the emergence of resistance in FLT3-mutated AML.